scholarly journals Publisher Correction: Sickle cell gene therapies approach watershed

Author(s):  
Cormac Sheridan
Keyword(s):  
BMJ ◽  
1955 ◽  
Vol 1 (4925) ◽  
pp. 1308-1311 ◽  
Author(s):  
G. M. Edington ◽  
H. Lehmann
Keyword(s):  

2012 ◽  
Vol 2 (2) ◽  
pp. 57-60
Author(s):  
Jayanti Mishra ◽  
Sanghamitra Pati ◽  
Mohammad Akhtar Hussain ◽  
Niraj Srivastava ◽  
Sindhubala Mishra

The highest frequency of sickle cell gene in India is reported in Odisha. The present study was taken up to assess the presence of sickle cell disease among febrile patients of a medical college of eastern Odisha. Patients referred from both pediatric and medicine department to the Hematology section of the department of Pathology, SCB Medical College, Cuttack were subjected to measurement of RBC indices, Sickling test, Haemoglobin Electrophoresis and Fetal Haemoglobin Estimation. Out of total 1000 referred patients 76(7.6%) were found to be positive for sickling. Two‐third of sicklingpositive patients had sickle cell trait with electrophoretic AS band. There was a significant association between age and positive sickling (χ2 = 24.357; df = 4, P = <0.0001). No significant association was observed between sickling and gender. Sickle cell positive cases are not uncommon in eastern Odisha. Our study demonstrated sickle cell trait to be more common among screened patients than other forms of sickle cell diseases.


2021 ◽  
Vol 3 ◽  
Author(s):  
Eleni Papanikolaou ◽  
Andreas Bosio

It has been over 30 years since visionary scientists came up with the term “Gene Therapy,” suggesting that for certain indications, mostly monogenic diseases, substitution of the missing or mutated gene with the normal allele via gene addition could provide long-lasting therapeutic effect to the affected patients and consequently improve their quality of life. This notion has recently become a reality for certain diseases such as hemoglobinopathies and immunodeficiencies and other monogenic diseases. However, the therapeutic wave of gene therapies was not only applied in this context but was more broadly employed to treat cancer with the advent of CAR-T cell therapies. This review will summarize the gradual advent of gene therapies from bench to bedside with a main focus on hemopoietic stem cell gene therapy and genome editing and will provide some useful insights into the future of genetic therapies and their gradual integration in the everyday clinical practice.


1962 ◽  
Vol 27 (5) ◽  
pp. 257-267 ◽  
Author(s):  
M.S. Mital ◽  
J.G. Parekh ◽  
P.K. Sukumaran ◽  
R.S. Sharma ◽  
P.J. Dave
Keyword(s):  

Hemoglobin ◽  
1996 ◽  
Vol 20 (3) ◽  
pp. 187-198 ◽  
Author(s):  
M. A. F. El-Hazmi ◽  
A. S. Warsy ◽  
A. R. Al-Swailem ◽  
A. M. Al-Swailem ◽  
H. M. Bahakim
Keyword(s):  

Blood ◽  
1955 ◽  
Vol 10 (4) ◽  
pp. 341-350 ◽  
Author(s):  
J. M. VANDEPITTE ◽  
WOLF W. ZUELZER ◽  
JAMES V. NEEL ◽  
J. COLAERT

Abstract It is pointed out that there are two outstanding (and not mutually exclusive) possible explanations for the persistence of the sickle cell gene in the face of strong negative natural selection. These are (1) "balanced polymorphism," and (2) a high spontaneous mutation rate. In Léopoldville, Belgian Congo, approximately 25 per cent of the natives exhibit the sickling phenomenon. Over a two and one-half year period 261 patients with sickle cell disease, distributed among 243 families, were seen at the Institute of Tropical Medicine in Léopoldville. A total of 233 of the 243 mothers of the patients in this series was tested for the sickling phenomenon. Only two failed to sickle. Hemoglobin from these two women was normal on paper electrophoresis. The occurrence of these two exceptional mothers can be explained on the basis of mutation at some stage of oogenesis resulting in a sickle cell gene. Alternate possible explanations include (1) transmission by the mother of some other abnormal gene affecting hemoglobin synthesis, (2) occurrence in the mother of a genetic modifier of the effects of the sickle cell gene, (or its normal allele), and (3) unreported adoption. These data make possible a preliminary calculation of the extent to which mutation may be responsible for maintaining the sickle cell gene. Calculations based on the assumption that both these exceptional mothers indicate the occurrence of a mutation will lead to maximal estimates of the rate of mutation of the sickle cell gene. This maximal estimate is 1.7 x 10-3 per gene per generation. This rate, although very high by the usual standards of human mutation rates, is only approximately one-tenth that necessary to offset natural selection in a population with 25 per cent sickling.


Sign in / Sign up

Export Citation Format

Share Document